Patient
SITE013-0042
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2025-10-23
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 9
Grade 3 Hyperthyroidism — outcome: RECOVERED/RESOLVED; onset 2022-06-07 (study day 41); relationship: not assessed
Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-06-02 (study day 36); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-31 (study day 34); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-26 (study day 29); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 18); relationship: NOT RELATED
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-14 (study day 17); relationship: NOT RELATED
Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-05 (study day 8); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-02 (study day 5); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-02 (study day 5); relationship: NOT RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.